Misoprostol in Refractory Neuralgic Pain: From Clinical Neurology to an EP-Receptor Hypothesis of Pharmacodynamic Persistence.
7 affiliations
- 1Independent Researcher, Geneva, IL 60134, USA.
- 2Neurovisual Science Technology, Via Tomaselli 43, 95125 Catania, Italy.
- 3Faculty of Medicine and Surgery, University of Enna "Kore", 94100 Enna, Italy.
- 4Mediterranean Foundation G.B. Morgagni, Ophthalmology Clinic, 95125 Catania, Italy.
- 5Eye Clinic, Department of Public Health, University of Naples Federico II, 80131 Naples, Italy.
- 6Department of General and Paediatric Ophthalmology, Medical University of Lublin, 20-079 Lublin, Poland.
- 7Department of Special Surgery, University of Jordan, Queen Rania St., Amman 11942, Jordan.
Abstract
This hypothesis originated from the first author's personal experience in adult neurology, in which selected refractory cranial or postherpetic neuralgias occasionally appeared to improve rapidly after off-label misoprostol. The original records are unavailable; these physician recollections are not efficacy data and serve only as the hypothesis generator. Independent published precedents are limited to small uncontrolled reports in multiple-sclerosis-associated trigeminal neuralgia. A further recollection was that perceived benefit often waned after several weeks at conventional daily exposure, whereas lower or intermittent exposure sometimes appeared to remain useful for longer; this observation is likewise unverifiable and does not define a therapeutic dose. Misoprostol is rapidly converted to misoprostol acid (plasma half-life of 20-40 min). We ask whether a brief, reversible exposure could produce pharmacodynamic persistence, defined here as a reproducible pain-relevant effect that outlasts measurable drug exposure, through EP-receptor trafficking, compartmentalized GPCR signaling, or downstream cellular changes. The model also predicts that the concentration-response relationship may be non-monotonic: increasing or repeated exposure could attenuate or reverse a favorable effect by recruiting opposing EP pathways or adaptive receptor/cellular responses. No direct evidence shows that misoprostol produces such persistence in neural tissue, and PGE2/EP signaling can also be pronociceptive. Receptor-resolved concentration-response and pulse-washout experiments must therefore separately demonstrate receptor signaling, persistent cellular change, altered neuronal excitability, and ultimately blinded analgesic benefit. Neuropathic corneal pain is considered only a secondary mechanistic model. No evidence-based dose can currently be recommended.
Related
- Clinical improvement despite rising anti-streptococcal antibody titers during adjunctive bacteriophage therapy in refractory PANDAS: a hypothesis-generating case report
- Unintended consequences of vaginal misoprostol use in a patient with hydatidiform mole : A case report
- Comparison of 25 µg Vaginal Misoprostol Versus Dinoprostone Gel for Induction of Labor in Term Prelabor Rupture of Membranes: A Retrospective Record-Based Observational Study
- Comparison of Two Misoprostol Doses for the Occurrence and Severity of Meconium-stained Liquor in Pre-labor Rupture of Membranes
- Misoprostol monotherapy versus adjunctive mechanical cervical ripening with Foley catheter or Dilapan-S for second-trimester termination of pregnancy: A randomized controlled trial.
BibTeX
@article{bukowy2026misoprostol,
title = {{Misoprostol in Refractory Neuralgic Pain: From Clinical Neurology to an EP-Receptor Hypothesis of Pharmacodynamic Persistence.}},
author = {Ronald B Bukowy and Dario Rusciano and Caterina Gagliano and Mario D Toro},
journal = {International journal of molecular sciences},
year = {2026},
month = sep,
doi = {10.3390/ijms27198455},
url = {https://europepmc.org/article/MED/42883704},
note = {CC BY},
}
RIS
TY - JOUR
TI - Misoprostol in Refractory Neuralgic Pain: From Clinical Neurology to an EP-Receptor Hypothesis of Pharmacodynamic Persistence.
AU - Ronald B Bukowy
AU - Dario Rusciano
AU - Caterina Gagliano
AU - Mario D Toro
PY - 2026
DA - 2026/09/22
JO - International journal of molecular sciences
DO - 10.3390/ijms27198455
UR - https://europepmc.org/article/MED/42883704
AB - This hypothesis originated from the first author's personal experience in adult neurology, in which selected refractory cranial or postherpetic neuralgias occasionally appeared to improve rapidly after off-label misoprostol. The original records are unavailable; these physician recollections are not efficacy data and serve only as the hypothesis generator. Independent published precedents are limited to small uncontrolled reports in multiple-sclerosis-associated trigeminal neuralgia. A further recollection was that perceived benefit often waned after several weeks at conventional daily exposure, whereas lower or intermittent exposure sometimes appeared to remain useful for longer; this observation is likewise unverifiable and does not define a therapeutic dose. Misoprostol is rapidly converted to misoprostol acid (plasma half-life of 20-40 min). We ask whether a brief, reversible exposure could produce pharmacodynamic persistence, defined here as a reproducible pain-relevant effect that outlasts measurable drug exposure, through EP-receptor trafficking, compartmentalized GPCR signaling, or downstream cellular changes. The model also predicts that the concentration-response relationship may be non-monotonic: increasing or repeated exposure could attenuate or reverse a favorable effect by recruiting opposing EP pathways or adaptive receptor/cellular responses. No direct evidence shows that misoprostol produces such persistence in neural tissue, and PGE2/EP signaling can also be pronociceptive. Receptor-resolved concentration-response and pulse-washout experiments must therefore separately demonstrate receptor signaling, persistent cellular change, altered neuronal excitability, and ultimately blinded analgesic benefit. Neuropathic corneal pain is considered only a secondary mechanistic model. No evidence-based dose can currently be recommended.
SN - 1422-0067
ER -